Common stock sold at $4.14 per share to RA Capital and other investors
By Devika Patel
Knoxville, Tenn., May 9 - Omeros Corp. said it plans a $16.16 million registered direct offering of stock.
The company will sell 3,903,004 common shares to RA Capital Management and other investors. The purchase price, of $4.14 per share, reflects a 1.97% premium to the $4.06 closing share price on May 8.
Settlement is expected May 14.
Proceeds will be used for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for research and development expenses. The proceeds may also be used for pre-clinical studies, capital expenditures, working capital and to advance Omeros' products towards commercialization.
Omeros is a biopharmaceutical company based in Seattle.
| Issuer: | Omeros Corp.
|
| Issue: | Common stock
|
| Amount: | $16,158,437
|
| Shares: | 3,903,004
|
| Price: | $4.14
|
| Warrants: | No
|
| Investor: | RA Capital Management
|
| Pricing date: | May 9
|
| Settlement date: | May 14
|
| Stock symbol: | Nasdaq: OMER
|
| Stock price: | $4.06 at close May 8
|
| Market capitalization: | $108.04 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
